Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OSBP | P22059 | 6/20 | 1.00 |
| ▸ | NR1H3 | Q13133 | 6/20 | 1.00 |
| ▸ | RORC | P51449 | 5/20 | 1.00 |
| ▸ | OSBP2 | Q969R2 | 3/20 | 1.00 |
| ▸ | CRYAB | P02511 | 1/20 | 1.00 |
| ▸ | HMGCR | P04035 | 1/20 | 1.00 |
| ▸ | ITGB3 | P05106 | 1/20 | 1.00 |
| ▸ | ITGAV | P06756 | 1/20 | 1.00 |
| ▸ | SREBF2 | Q12772 | 1/20 | 1.00 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.91 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.91 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.91 |
| ▸ | USP2 | O75604 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.80 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.80 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.74 |
| ▸ | DHCR24 | Q15392 | 1/20 | 0.73 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6388323 | 1.00 | OSBP (1.00) | OSBPNR1H3RORCOSBP2CRYAB | |
| SCHEMBL15435130 | 1.00 | OSBP (1.00) | OSBPNR1H3RORCOSBP2CRYAB | |
| SCHEMBL3420850 | 1.00 | OSBP (1.00) | OSBPNR1H3RORCOSBP2CRYAB | |
| SCHEMBL177268 | 1.00 | OSBP (1.00) | OSBPNR1H3RORCOSBP2CRYAB | |
| SCHEMBL25035613 | 1.00 | OSBP (1.00) | OSBPNR1H3RORCOSBP2CRYAB | |
| SCHEMBL177267 | 1.00 | OSBP (1.00) | OSBPNR1H3RORCOSBP2CRYAB | |
| SCHEMBL17049791 | 1.00 | OSBP (1.00) | OSBPNR1H3RORCOSBP2CRYAB | |
| SCHEMBL14420777 | 1.00 | OSBP (1.00) | OSBPNR1H3RORCOSBP2CRYAB | |
| SCHEMBL22559541 | 1.00 | OSBP (1.00) | OSBPNR1H3RORCOSBP2CRYAB | |
| SCHEMBL20299556 | 1.00 | OSBP (1.00) | OSBPNR1H3RORCOSBP2CRYAB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637722-A1 | 25-HYDROXY-CHOLEST-5-EN-3-SULFATE CHOLINE, FORMULATIONS THEREOF AND METHODS FOR PREPARING, AND MEDICAL USES OF SAME | Durect Corporation (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4638463-A1 | SALTS INCLUDING CRYSTALLINE SALTS OF 25-HYDROXY-CHOLEST-5-EN-3-SULFATE AND METHODS FOR PREPARING SAME | Durect Corporation (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-2024138203-A1 | 25-HYDROXY-CHOLEST-5-EN-3-SULFATE CHOLINE, FORMULATIONS THEREOF AND METHODS FOR PREPARING, AND MEDICAL USES OF SAME | DURECT CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024138203-A1 | 25-HYDROXY-CHOLEST-5-EN-3-SULFATE CHOLINE, FORMULATIONS THEREOF AND METHODS FOR PREPARING, AND MEDICAL USES OF SAME | DURECT CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-4359420-A1 | 25-HYDROXY-CHOLEST-5-EN-3-SULFATE CHOLINE AND METHODS FOR PREPARING, AND USES OF, SAME | Durect Corporation (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20230181744-A1 | COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES | FUDAN UNIVERSITY (CN) | 2023-06-15 | — | — | US | disclosed |
| US-20230181744-A1 | COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES | FUDAN UNIVERSITY (CN) | 2023-06-15 | — | — | US | disclosed |
| US-20230056273-A1 | CRYSTALLINE AND LIQUID CRYSTALLINE 25-HYDROXY-CHOLEST-5-EN-3-SULFATE SODIUM AND METHODS FOR PREPARING SAME | JPMORGAN CHASE BANK, N.A. | 2023-02-23 | — | — | US | disclosed |
| WO-2022272103-A1 | 25-HYDROXY-CHOLEST-5-EN-3-SULFATE CHOLINE AND METHODS FOR PREPARING, AND USES OF, SAME | DURECT CORPORATION (US) | 2022-12-29 | — | — | WO | disclosed |
| EP-4081028-A1 | CRYSTALLINE AND LIQUID CRYSTALLINE 25-HYDROXY-CHOLEST-5-EN-3-SULFATE SODIUM AND METHODS FOR PREPARING SAME | Durect Corporation (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-115103591-A | Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sodium sulfate and process for preparing same | 度勒科特公司 | 2022-09-23 | — | — | CN | disclosed |
| WO-2021213518-A1 | COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES | 复旦大学 (CN) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021133976-A1 | CRYSTALLINE AND LIQUID CRYSTALLINE 25-HYDROXY-CHOLEST-5-EN-3-SULFATE SODIUM AND METHODS FOR PREPARING SAME | DURECT CORPORATION (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021120127-A1 | METHOD FOR PREPARING CHOLESTEROL, DERIVATIVE AND ANALOGUE THEREOF | 湖南科瑞生物制药股份有限公司 | 2021-06-24 | — | — | WO | disclosed |
| WO-2021121239-A1 | METHOD FOR PREPARING CHOLESTEROL, DERIVATIVE THEREOF, AND ANALOG THEREOF | 湖南科瑞生物制药股份有限公司 | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181744-A1 | COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES | MAP1LC3B, MAP1LC3A, SQSTM1 | OSBP 148/4885NR1H3 42/4885RORC 483/4885 |
| US-20230056273-A1 | CRYSTALLINE AND LIQUID CRYSTALLINE 25-HYDROXY-CHOLEST-5-EN-3-SULFATE SODIUM AND METHODS FOR PREPARING SAME | CYP27A1, CYP46A1, PCSK9 | OSBP 329/4885NR1H3 5/4885RORC 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.